Panel Discussion: Forging Strategic Pharma & Biotech Collaborations to Accelerate Induced Proximity Success
Time: 3:30 pm
day: Day Two
Details:
- What are the key partnership models – licensing, co-development, strategic acquisitions – between big pharma and small biotechs for advancing induced proximity programs effectively?
- How can cost efficient collaborations with academia and CROs help inform start-ups on resource allocation to de-risk induced proximity platforms before major investments?
- How can pioneering biotechs strategically frame their programs as must-have assets to big pharma to secure collaborations to advance novel proximity-based drug candidates?